HYPNONAG : Therapeutic Communication Versus Traditional Method for Naso-gastric Intubation in Haematology
NCT05790733 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 180
Last updated 2024-10-09
Summary
Caloric intake is a determining factor in patients with hematological malignancies and hospitalized for prolonged aplasia following chemotherapy. The nutritional supplement is administered either parenterally or enterally through the placement of a nasogastric sonde (NGS). This last option has shown its advantage compared to parenteral nutrition in terms of preventing infections, the incidence of graft-versus-host disease in allograft patients, and the quality of resumption of oral nutrition during of returning home.
NGS allows the administration of an intake of 2000 calories/day, deemed necessary to mitigate the risk of undernutrition in patients hospitalized for more than 3 weeks and in the majority of cases unable to eat enough food mainly due to chemotherapy-induced mucositis. . The choice between enteral feeding by NGS and parenteral nutrition is the subject of controversial studies, with each team choosing one of the two options.
The installation of the NGS is often recognized as a traumatic gesture for patients but also invasive by caregivers.
The patient's anxiety, the intrusive and traumatic nature of the NGS can sometimes result in a failure of the gesture, a secondary refusal of the patient, or a reluctance of the caregiver to proceed with the gesture. Since 2013, NGS have been placed with the assistance of the nurse who practices hypnosis in the hematology department of the Rennes University Hospital. This invites the patient to pose his SNG without local anesthesia and in a completely autonomous way. The patient is thus able to place the NGS again if necessary during his hospitalization, and during subsequent hospitalizations. A retrospective and monocentric study carried out at the University Hospital of Rennes in 38 patients showed that all were able to perform NGS independently thanks to the hypnotic approach. It was observed a real comfort for the patient, and moreover this technique did not add extra work for the staff. The patient becomes autonomous and actor of his care.
Conditions
- Aplasia
- Chemotherapy Effect
Interventions
- OTHER
-
Standard intubation
This involves the use of 5% Xylocaine nebulizer spray and a single-use cannula. The nurse checks its expiry date and that the quantity is sufficient to practice the 7 instillations in one nostril and the other 7 in the mouth. A waiting time is respected and the installation of the NGS can begin. She will also set up a fast for 2 hours after this local anesthesia.
- OTHER
-
Hypnosis
Hypnosis is a particular psychological state marked by the functioning of the individual at a level of attention other than the ordinary state of consciousness. It can, under certain conditions, give the appearance of sleep or somnambulism without sharing all the characteristics. As part of the treatment, hypnosis is widely used for pain control. The adverse effects reported are nil. One of its main benefits is improved patient comfort. Another benefit is the reduction of exposure to anesthetic products. The installation of the NGS with hypnosis will be carried out according to the protocol set out in appendix 4.
Sponsors & Collaborators
-
Rennes University Hospital
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-07-01
- Primary Completion
- 2026-02-01
- Completion
- 2026-08-01
Countries
- France
Study Locations
More Related Trials
-
Efficacy and Safety of Non Invasive Vagal Stimulation to Prevent Chemotherapy-induced Nausea
NCT04937309 ·Status: UNKNOWN ·Phase: NA
-
Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer
NCT03040726 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer
NCT05841849 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Clinical on the Safety and Efficacy of Fosaprepitant Dimeglumine for Injection in the Prevention of CINV.
NCT05755659 ·Status: UNKNOWN ·Phase: NA
-
Prevalence Study of Adrenal Suppression After Corticosteroids During Chemotherapy
NCT01209507 ·Status: COMPLETED
-
Palonosetron and Dexamethasone With or Without Dronabinol in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy For Cancer
NCT00553059 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Participants Who Have Experienced CINV(Chemotherapy-Induced Nausea and Vomiting) During the Previous Cycle of Low Emetogenic Chemotherapy (LEC)
NCT01054456 ·Status: COMPLETED ·Phase: PHASE2
-
Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal Cancer
NCT05564286 ·Status: COMPLETED ·Phase: PHASE3
-
Effectiveness and Quality of Life Analysis of Palonosetron Against Ondansetron Combined With Dexamethasone and Fosaprepitant in Prevention of Acute and Delayed Emesis Associated to Chemotherapy Moderate and Highly Emetogenic in Breast Cancer.
NCT03606369 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC)
NCT06904235 ·Status: RECRUITING ·Phase: PHASE2
-
Study for The Prevention Of Nausea in Cancer Patients Receiving Highly Emetogenic Cisplatin Based Chemotherapy
NCT00169572 ·Status: COMPLETED ·Phase: PHASE2
-
Conventional Prophylactic Oral Dexamethasone vs Short-course IV Dexamethasone in Paclitaxel Hypersensitivity
NCT03598426 ·Status: COMPLETED ·Phase: PHASE3
-
Multi-day Doses in Prevention of Nausea and Emesis
NCT00600353 ·Status: COMPLETED ·Phase: PHASE2
-
Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC)
NCT01640340 ·Status: COMPLETED ·Phase: NA
-
Dexmedetomidine or Dexmedetomidine Combined With Dexamethasone on Postoperative Nausea and Vomiting in Breast Cancer
NCT02550795 ·Status: COMPLETED ·Phase: NA
-
Efficacy and Safety of Netupitant and Palonosetron Hydrochloride Capsules in Preventing Nausea and Vomiting Induced by Radiochemotherapy in Head and Neck Squamous Cell Carcinoma
NCT06102447 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Buccal Film Versus IV Injection Palonosetron for Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting
NCT04592198 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment Algorithm for Nausea and Vomiting in the Palliative Phase
NCT03017391 ·Status: UNKNOWN ·Phase: PHASE4
-
Observational Study on the Use of Akynzeo® in Patients Receiving HEC
NCT03649230 ·Status: COMPLETED
-
A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting
NCT02517021 ·Status: COMPLETED ·Phase: PHASE3
-
Palonosetron, Ondansetron, and Dexamethasone for Delayed Nausea and Vomiting in Autologous Transplant Patients
NCT01370408 ·Status: COMPLETED ·Phase: PHASE2
-
Electroacupuncture Plus Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer
NCT06314906 ·Status: RECRUITING ·Phase: PHASE3
-
Efficacy and Safety of Palonosetron Hydrochloride in the Prevention of Nausea and Vomiting
NCT01481831 ·Status: COMPLETED ·Phase: PHASE4
-
Effects of Short-term Therapeutic Fasting on Nausea and Vomiting Due to Chemotherapy
NCT04141514 ·Status: RECRUITING ·Phase: NA
-
Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting
NCT01432015 ·Status: COMPLETED ·Phase: PHASE4